FCRL5/FcRH5/IRTA2 Antibody (1010552) [Alexa Fluor® 700]

• Reactivity: Hu
• Applications: Flow
• Clone: 1010552
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 700

FCRL5/FcRH5/IRTA2 Antibody (1010552) [Alexa Fluor® 700] Summary

• Immunogen: Mouse myeloma cell line, NS0-derived human FCRL5 protein
  Gln16-Arg844
  Accession # Q96RD9
• Specificity: Detects human FCRL5 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25-1 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FCRL5/FcRH5/IRTA2 Antibody (1010552) [Alexa Fluor® 700]

• BXMAS1
• BXMAS1MGC119592
• CD307
• CD307e antigen
• CD307e
• DKFZp667E2019
• DKFZp667F216
• Fc receptor homolog 5
• Fc receptor-like 5
• Fc receptor-like protein 5
• FcRH5
• FCRH5MGC119593
• FCRL5
• FcR-like protein 5
• FLJ00333
• FLJ00397
• IFGP5
• Immune receptor translocation-associated protein 2
• immunoglobulin superfamily receptor translocation associated 2 (IRTA2)
• IRTA2
• IRTA2MGC119590
• PRO820

Background

Fc Receptor-Like 5 (FCRL5), also known as FcRH5, IRTA2, and CD307, is a 120 kDa protein with sequence homology to classical Fc receptors. The type 1 transmembrane FCRL proteins contain from three to nine immunoglobulin-like domains. They are differentially expressed within the B cell lineage and can either promote or inhibit B cell proliferation and activation (1, 2). According to R&D Systems testing, FCRL5 binds to purified human IgG with high affinity. Mature human FCRL5 consists of a 836 amino acid (aa) extracellular domain (ECD) with nine Ig-like domains, a 21 aa transmembrane segment, and a 105 aa cytoplasmic domain with one immunotyrosine activation motif (ITAM) and two immunotyrosine inhibitory motifs (ITIMs) (1, 3). Mouse FCRL5 contains only five Ig-like domains in its ECD. It shares 49% aa sequence identity with human FCRL5 within common regions. Alternate splicing of human FCRL5 generates isoforms that consist of approximately the first one, six, or eight Ig-like domains (3, 4). FCRL5 expression is restricted to mature B lineage cells in lymphoid tissues and blood (3, 5‑7). Its ligation inhibits signaling through the B cell antigen receptor (8). Epstein-Barr virus transformation of B cells induces the up‑regulation of surface FCRL5 by a direct effect of its EBNA2 protein on FCRL5 gene transcription (9). The FCRL5 gene maps to the 1q21 chromosomal locus, a common site of rearrangements in B cell malignancies, and the FCRL5 protein is preferentially expressed in cell lines with 1q21 abnormalities (3). FCRL5 is up‑regulated on tumor cells in some types of B cell malignancies (6, 10‑12). In addition, soluble FCRL5 is elevated in the serum of many B cell leukemia patients (11, 13).

1. Davis, R.S. (2007) Annu. Rev. Immunol. 25:525.
2. Maltais, L.J. et al. (2006) Nat. Immunol. 7:431.
3. Hatzivassiliou, G. et al. (2001) Immunity 14:277.
4. SwissProt # Q96RD9.
5. Miller, I. et al. (2002) Blood 99:2662.
6. Polson, A.G. et al. (2006) Int. Immunol. 18:1363.
7. Vidal-Laliena, M. et al. (2005) Cell. Immunol. 236:6.
8. Haga, C.L. et al. (2007) Proc. Natl. Acad. Sci. 104:9770.
9. Mohan, J. et al. (2006) Blood 107:4433.
10. Ise, T. et al. (2005) Clin. Cancer Res. 11:87.
11. Ise, T. et al. (2007) Leukemia 21:169.
12. Kazemi, T. et al. (2009) Cancer Immunol. Immunother. 58:989.
13. Ise, T. et al. (2006) Clin. Chem. Lab. Med. 44:594.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q96RD9(Human)